Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kindred Group announces changes in the Board of Directors

Kindred Group plc (“Kindred” or the “Company”) today announces that after settlement of the public offer launched by La Française des Jeux on Kindred, its Board of Directors has received the resignations of the Chairman of the Board, Evert Carlsson, and the Directors James H. Gemmel, Cédric Boireau, Andrew McCue, Jonas Jansson and Kenneth Shea, which resignations have been rendered effective today, on 14 October 2024. Heidi Skogster and Martin Randel will remain directors until their term of office expiring on Kindred’s next annual general meeting to be held in 2025. In accordance with

#24-355 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B62Z3C74 Issuer Name Fidelity China Special Situations PLC UK or Non-UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name City of London Investment Management Company Limited City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from

Annual Financial Report Availability

Fidelity Emerging Markets Limited Annual Report and Accounts Following the release by Fidelity Emerging Markets Limited (the "Company") on 9 October 2024 of the Company's Full Year Results Announcement for the year ended 30 June 2024, the Company announces that it has published the 2024 Annual Report and Accounts. The document is available to view on the Company's website and a copy has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism Printed copies of the Annual Financial

Director/PDMR Shareholding

FIDELITY ASIAN VALUES PLC (the "Company") Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them The Company announces transactions in ordinary shares of the Company ("Shares") by a person discharging managerial responsibility ("PDMR"). The transactions were notified to the Company on 14 October 2024. The number of Shares acquired and the transaction prices of those Shares is as follows: +--+----------------------------+------------------+----------------+|1 |Details of the person

Mobile Casinos for Real Money in Canada

Mobile casinos in Canada come in many shapes and sizes, with a variety of games, themes and designs. You also have the option of playing using a casino app or mobile site. There is no correct way to play at a casino, but there are a few things that are worth considering so that you can make sure you get the best experience. What Mobile Casinos Offer Canadian Players Mobile casinos are those that can be played on mobile phones, tablets or other handheld devices, whether through apps or your chosen browser. There are many ways in which sites can be designed, from the games they

BioGaia AB’s Nomination Committee for the 2025 Annual General Meeting

BioGaia AB’s Nomination Committee for the Annual General Meeting 2025 has been appointed based on the ownership structure as of June 30, 2024. The Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Jacob Sellman, EQT, Jannis Kitsakis, appointed by AP4, and Thomas Brown, Premier Miton Investors. In addition, Peter Rothschild is a member of the

Nomination committee for the 2025 Annual General Meeting

In accordance with the resolution by the Annual General Meeting of Billerud, the Chairman of the Board of Directors has convened a Nomination Committee for the Annual General Meeting 2025, appointed by the major shareholders in the company.The Nomination Committee consists of Anders Oscarsson, appointed by AMF Pension & Funds, Michael M.F. Kaufmann, appointed by Frapag Beteiligungsholding AG, Jan Särlvik, appointed by Fourth Swedish National Pension Fund and Oscar Bergman, appointed by Swedbank Robur Funds. Information about the work of the Nomination Committee can be found at Billerud’s

Inside information, profit warning: Kamux lowers its outlook for the year 2024

Kamux Corporation, Inside information, 14.10.2024 at 17:00    Inside information, profit warning: Kamux lowers its outlook for the year 2024 Kamux lowers its outlook for the year 2024 due to significantly lower than expected sales and the subsequent operating loss in Sweden in the third quarter. Kamux now expects the adjusted operating profit for 2024 to be EUR 15–17 million. Previously Kamux expected its adjusted operating profit for 2024 to exceed its 2023 adjusted operating profit, which was EUR 18.0 million. Rationale for updating the outlook The corrective actions that are

Invitation to conference call Byggmax Group's Interim Report January 1 – September 30, 2024

Byggmax interim report for the third quarter 2024 will be published on Friday, October 25, at approximately 07.45 CET. A teleconference will be held on the same day, in English, at 10.30 CET.Byggmax CEO Karl Sandlund and CFO Helena Nathhorst will present the results for the third quarter 2024 and answer questions.   A presentation will be available on our website from 08.30 CET on October 25, https://om.byggmax.se/en/investors/presentations.   To join the conference call the following numbers: SE (Local): +46 10 884 80 16 PIN: 745752 UK (Toll Free): +44 800 358 1035 PIN:

Dicot Pharma informs that two additional patents are in the process of being approved in USA

Uppsala, Sweden, October 14, 2024. Dicot Pharma announces today that the company has received Notice of Allowance for two US patent applications from the US Patent and Trademark Office (USPTO). These include, among other things, the active substance in LIB-01. A Notice of Allowance means that the USPTO intends to grant a patent once certain formal steps have been taken.Recently, Dicot Pharma announced that it received a Notice of Allowance from the USPTO regarding a patent application (No. 18/496,049) covering key steps in the manufacture of the active substance in LIB-01. Today, the

Aker Horizons ASA: Minutes from Extraordinary General Meeting

An extraordinary general meeting of Aker Horizons ASA was today held as a digital meeting with online participation. All resolutions were made in accordance with the proposals set out in the meeting notice published on 23 September 2024. Minutes of the meeting are attached and available on https://akerhorizons.com/investors/shareholder-center/extraordinary-general-meeting/.Following the general meeting’s resolutions, the shareholder-elected board members of Aker Horizons ASA comprise the following: · Kristian Monsen Røkke (Chair) · Øyvind Eriksen (Deputy Chair) · Lone Fønss

CORRECTION: Notice to the Extraordinary General Meeting of Eevia Health Abp

The notice has the following corrections (in bold): The Record date is October 23 and not October 24. The deadline for nominee registered shares is October 30 not October 29. Shareholders in Sweden must be registered in the shareholder's register held by Euroclear Sweden AB Shares on October 21, not October 25.  Request for temporary registration in shareholder register for shares in Sweden must be made latest October 28, not October 31.This notice is given to the shareholders of Eevia Health Abp (Plc) for an Extraordinary General Meeting to be held on November 4, 2024, at noon (Finnish

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (11 October 2024)

STORA ENSO OYJ STOCK EXCHANGE RELEASE 14 October 2024 at 16:00 EESTStora Enso Oyj received a notification pursuant to chapter 9, section 5 of the Securities Market Act from BlackRock, Inc on 14 October 2024. On 11 October 2024, BlackRock's holding in Stora Enso’s shares increased above the 5 percent threshold. +----------------+--------------+-----------------------------+---------------+|  |% of shares |% of shares and voting rights|Total of both || |and voting |through financial instruments|in % (7.A + || |rights |(

K2A sends notice of partial repayment of notes issued under the Company's MTN program

K2A Knaust & Andersson Fastigheter AB (publ) (the “Company” or “K2A”) has today sent notice of partial repayment to all holders of the Company's outstanding medium term notes with loan number 102 (ISIN: SE0013104791) (the "Outstanding Notes"), issued under the Company's MTN program. Repayment will take place in accordance with the terms and conditions for the Outstanding Notes to an amount of approx. SEK 56 million. The total nominal amount for the Outstanding Notes after the repayment will be SEK 200 million. The partial repayment will be financed with funds from the Company's recently

Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna

AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of ulcerative colitis, and presents new results from the Aqilion preclinical development program at the United European Gastroenterology (UEG) Week in Vienna.Wayne Russell, Senior Director Translational Biology and Innovation, presents new preclinical data describing the drug candidate AQ312 in several gastrointestinal disease models. The presentation will take place during UEG Week 2024 in Vienna on October 12-15 .   Aqilion is developing the drug candidate AQ312, an

Summa Equity invests in EA Technology to accelerate the energy transition through a smarter grid

October 14[th], 2024, Stockholm: Impact investment firm Summa Equity (“Summa”) today announces its investment in EA Technology (“EA”), partnering with selling management and employee shareholders. EA is a leading solutions provider for monitoring and management of electricity grids and assets, headquartered in the UK.Founded in 1966, EA Technology has for decades been a pioneer within research, development and innovation in the UK electricity industry. The Company’s industry-leading product suite of smart grid hardware, software and services today serves a global customer base across five

Nexam Chemical presents third quarter for 2024 on October the 18[th] at 12:00 CET

On October the 18[th] 2024 at 08:18 CET Nexam Chemical will publish the report for the third quarter for 2024. The report and the presentation will be available at the company website.In connection with the release - analysts, investors and media are hereby invited to a live streamed presentation at 12:00 CET where Ronnie Törnqvist, CEO, and Marcus Nyberg, CFO, will present and comment the report. The presentation will be held in English via https://www.youtube.com/watch?v=4VPu4RaQjMg No pre-registration is required. Please connect 5-10 minutes prior to the scheduled start time to

Attendo's third quarter report for 2024 to be published on 24 October - Invitation to presentation

On 24 October 2024 around 08:00 am (CET), Attendo will present the report for the third quarter of 2024. A webcast presentation will be held at 10:00 am (CET) on the same day.The presentation will be hosted by Attendo’s CEO Martin Tivéus and CFO Mikael Malmgren. The presentation will be held in English. You can follow the presentation on the following page: https://ir.financialhearings.com/attendo-q3-report-2024   Analysts and investors will have the opportunity to ask questions during the presentation by calling in. To obtain call-in details, please send your request to:

There are no items matching the current filter
There are no more items matching the current filter
Back to top